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Recently, a (pro)renin receptor has been identified which
mediates profibrotic effects independent of angiotensin II.
Because antihypertensive therapy induces renal injury in the
clipped kidney of two kidney-1-clip hypertensive rats, we
examined the regulation of renin and the (pro)renin receptor
in this model. Hypertensive Goldblatt rats were treated with
increasing doses of the vasopeptidase inhibitor AVE 7688
after which the plasma renin and prorenin as well as the
renal renin and (pro)renin receptor expression were
measured. The vasopeptidase inhibitor dose-dependently
lowered blood pressure, which was associated with a massive
increase in plasma prorenin and renin as well as increased
renal renin expression. The (pro)renin receptor was
upregulated in the clipped kidney of the Goldblatt rat
indicating a parallel upregulation of renin and its receptor
in vivo. Immunohistochemistry showed a redistribution of
renin upstream from the glomerulus in preglomerular vessels
and renin staining in tubular cells. Expression of the
(pro)renin receptor was increased in the vessels and tubules.
This upregulation was associated with thickening of
renin-positive vessels and tubulointerstitial damage. We
propose that renin and the (pro)renin receptor may play a
profibrotic role in the clipped kidney of Goldblatt rats treated
for hypertension.
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The renin-angiotensin system is a central regulator of blood
pressure. Seventy years ago the landmark experiments of
Goldblatt established that the system could also be respon-
sible for disease.1 Reduction of blood pressure by blockade of
the renin-angiotensin system has well-known and established
beneficial effects in chronic kidney disease.2,3 However, in
case of renal artery stenosis, blood pressure reduction might
have detrimental effects for the stenosed kidney due to renal
failure. Prolonged blood pressure reduction in renovascular
hypertension induces severe tubulointerstitial damage in the
clipped kidney.4–7 The mechanisms and mediators of this
injury are poorly defined. However, it is known that in the
clipped kidney renin levels are increased. From this point of
view, it is interesting that a renin receptor was recently
identified which binds prorenin and renin.8 As both renin
and prorenin are capable of binding with similar affinity,
it was named (pro)renin receptor. Upon receptor binding
the enzymatic activity of renin is increased and prorenin is
non-proteolytically activated. This indicates that the receptor
may be involved in local angiotensin II (Ang II) forma-
tion.9,10 In addition, profibrotic signaling pathways are
activated independent of Ang II.11 Because it is unknown
how the (pro)renin receptor is regulated in vivo, especially in
high renin conditions, we examined renin and (pro)renin
receptor expression in the clipped kidney of Goldblatt rats.
Moreover, the effects of blood pressure reduction by
vasopeptidase inhibition on renin and (pro)renin receptor8
in the clipped kidney of Goldblatt hypertensive rats were
studied.
RESULTS
Systolic blood pressure was increased in the Goldblatt rats
and was dose-dependently reduced by the vasopeptidase
inhibitor (Goldblatt rats 17674 mm Hg, Goldblattþ 50 mg/kg
AVE 16878 mm Hg, 150 mg/kg 13377 mm Hg, 450 mg/kg
AVE 9474 mm Hg). Blood pressure reduction by AVE
induced a dose-dependent increase of interstitial fibrosis in
the clipped kidney as shown recently.7 Treatment of healthy
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normotensive rats with the vasopeptidase inhibitor (450 mg/kg)
lowered blood pressure to 8574 mm Hg.7
Plasma renin and prorenin concentrations were increased
in untreated Goldblatt rats and increased further with
reduction of blood pressure (Figure 1a and b). The rise
in plasma renin exceeded the rise in plasma prorenin,
in agreement with the earlier observation that chronic
stimulation causes more prorenin to be converted into renin,
thereby leading to an increased renin/prorenin ratio in
plasma.12
Real-time reverse transcription-polymerase chain reaction
(PCR) showed that renal renin mRNA was upregulated in the
clipped kidney of Goldblatt rats and that blood pressure
reduction was associated with a massive dose-dependent
upregulation of renin (Figure 1c). In parallel to renin,
(pro)renin receptor mRNA was also upregulated in the
clipped kidney of Goldblatt rats and antihypertensively
treated rats (Figure 1d). To study whether this effect is
specific for the clipped kidney, we evaluated the expression of
renal renin and (pro)renin receptor in healthy normotensive
rats treated for 6 weeks with the vasopeptidase inhibitor
(450 mg/kg). Blood pressure reduction induced a 92.577.4-
fold increase in renal renin mRNA. However, (pro)renin
receptor mRNA was reduced 0.8270.06-fold compared to
untreated normotensive rats.
Immunohistochemistry against renin revealed an increas-
ing redistribution of renin upstream from the glomerulus in
preglomerular vessels of antihypertensively treated rats
suggesting a recruitment of smooth muscle cells to the
renin-expressing population (Figure 2a–e). Dose-dependent
induction of renin was confirmed by morphometry of the
renin-positive area (Figure 2f). Also the number of glomeruli
with staining against renin of the preglomerular vessels
increased significantly (Figure 2g). An increased thickness of
the wall of preglomerular vessels was observed in treated rats
compared to untreated Goldblatt rats (Figure 2h and i). In
consecutive renal sections, the same preglomerular vessel
stained positive for renin and a-smooth muscle cell actin
(Figure 2j and k). Some particular distal tubular cells of
antihypertensively treated rats were positive for renin protein
as well (Figure 2l and m). One of 10 kidneys in the AVE
50 mg/kg, two of 11 in AVE 150 mg/kg and five of 10 in AVE
450 mg/kg group showed tubular renin staining. The number
of renin-positive tubuli divided by all tubuli averaged
0.0370.02 in the moderate, 0.0270.01 in the intermediate,
and 0.1570.08 in the intensified blood pressure reduction
group. No renin-positive tubuli were found in controls and
Goldblatt rats. In situ hybridization for renin showed weak
preglomerular expression in controls (Figure 3a and b),
increased expression in Goldblatt rats and very strong renin
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Figure 1 | Plasma and renal renin. (a and b) Plasma prorenin and renin levels increased with blood pressure reduction. (c) Real-time
reverse transcription-PCR analysis of kidney cortex revealed a significant upregulation of renin expression in the clipped kidney of
antihypertensively treated rats. The increased expression of renin was matched by an enhanced expression of the (pro)renin receptor in treated
and nontreated Goldblatt rats as shown in (d). *Po0.007, **Po0.002 vs controls, #Po0.012, ##Po0.004, ###Po0.001 vs Goldblatt.
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expression in the antihypertensively treated Goldblatt rats
(Figure 3c and d). Tubular transcription of renin was not
found in any group.
Weak (pro)renin receptor mRNA expression was found in
glomeruli, tubules, and vessels in controls (Figure 3e–g).
Enhanced expression was seen in proximal and particularly in
distal tubules and arteries of antihypertensively treated rats
matching the results of the PCR data (Figure 3h–j).
(Pro)renin receptor protein is predominantly expressed in
distal tubular cells and visceral epithelial cells of glomeruli
(Figure 4a). To a lesser extent (pro)renin receptor is also
found in proximal tubules and larger vessels. There was no
co-localization of preglomerular renin and (pro)renin
receptor (Figure 4a and b). However, the tubules that were
positive for renin, also showed (pro)renin receptor expres-
sion (Figure 4c and d).
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Figure 2 | Immunohistochemical localization of renin protein. (a and b) Small parts of preglomerular vessels adjacent to the
glomerulus-stained positive for renin in controls and hypertensive rats. (c–e) With increasing blood pressure reduction a dose-dependent
increase of the renin-positive area with a redistribution of renin upstream from the glomerulus in preglomerular vessels was found.
(f) A quantification of the renin-positive area by morphometry is shown. (g) In addition, the number of glomeruli with renin-positive
preglomerular vessels increased significantly with blood pressure reduction. (h and i) A significant increase in preglomerular vessel wall
thickness was found in antihypertensively treated rats (arrow). This is a combination of hyperplasia and conversion of smooth
muscle cells into renin producing epithelial cells. (j and k) The same preglomerular vessels stain positive for renin and a-smooth muscle
cell actin on consecutive sections. (l and m) In addition, renin staining was found in tubular cells of antihypertensively treated rats. *Po0.004
vs controls #Po0.003, ##Po0.001 vs Goldblatt.
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DISCUSSION
Deleterious effects of blood pressure reduction can occur in
patients with reduced renal perfusion due to stenosis of the
renal artery or due to arteriosclerotic stenoses of intrarenal
small vessels.13 We and others have described the tubulo-
interstitial damage induced in these kidneys by antihy-
pertensive therapy.4,6,14 However, little is known about
the mechanisms responsible for this pronounced injury in
the clipped kidney.
In this study, we showed that the renal renin and the
(pro)renin receptor are upregulated in parallel in the clipped
kidney of Goldblatt hypertensive rats. Moreover, blood
pressure reduction induced a further increase in renal renin
expression in the clipped kidney. The in vivo regulation of the
(pro)renin receptor in the kidney is largely unknown. In
healthy rats, upregulation of renal renin along with a
downregulation of (pro)renin receptor was found during
angiotensin-converting enzyme inhibition and volume
depletion.15 This is in agreement with a recent observation
that activation of the (pro)renin receptor by renin results in
translocation of the transcription factor promyelocytic zinc
finger protein to the nucleus which subsequently represses
transcription of the (pro)renin receptor itself.16 Because
lowering of blood pressure in healthy rats also induced renal
renin expression without upregulation of the (pro)renin
receptor expression, the parallel increments in the clipped
kidney are apparently specific for Goldblatt hypertension and
not a common regulatory mechanism.
Antihypertensive therapy induces renin expression in the
clipped kidney. Renin protein was predominantly expressed
in preglomerular vessels, but also weakly in tubules, which
has been described previously.17 The renin positivity of the
preglomerular vessels may be due to conversion of vascular
smooth muscle cells into renin producing epithelial cells.
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Figure 3 | Renin and (pro)renin receptor expression. In situ hybridization of renin showed weak expression in controls as shown
in the autoradiograph of (a) a whole kidney slice. (b) The weak preglomerular staining is shown in more detail. In contrast, heavy staining
of preglomerular vessels was found after blood pressure reduction as shown in the (c) autoradiograph and (d) in more detail. (e–g)
In situ hybridization of the (pro)renin receptor revealed only weak glomerular, tubular, and vessel staining in controls. (h–j) In contrast,
enhanced staining was found in proximal and distal tubules as well as intrarenal vessels of antihypertensively treated rats.
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In consecutive section, the preglomerular vessels stained
positive for renin and smooth muscle cell actin. However, for
a definitive proof this issue needs further investigation, that is
by dual label experiments with vascular and epithelial
markers. As renin transcription was only found in preglo-
merular vessels, tubular renin is therefore probably derived
from peritubular capillaries or the ultrafiltrate. Reabsorbed
renin may bind to the (pro)renin receptor, which was
specifically upregulated in tubules in Goldblatt rats. More-
over, in tubules renin colocalizes with the (pro)renin receptor
and may upon binding cause tubulointerstitial injury
through enhanced Ang II formation, which is known to
initiate fibrotic pathways. However, blockade of angiotensin-
converting enzyme as done in this study by using the
vasopeptidase inhibitor, will suppress the generation of
deleterious Ang II.18–20 angiotensin-converting enzyme is
the predominant, if not the only, angiotensin-converting
enzyme in the kidney,18,19,21 and the bulk of renal Ang II is
produced locally at renal tissue sites.20 Therefore, the
question arises, how fibrosis is mediated in the face of
reduced renal Ang II generation. A plausible candidate is the
recently cloned (pro)renin receptor. Huang et al. recently
showed that signaling of the (pro)renin receptor after
binding of renin has profibrotic effects independent of Ang
II formation in vitro.1,11 Furthermore, data by Ichihara22,23
suggest that binding of prorenin to the (pro)renin receptor
causes damage in hypertensive and diabetic renal injury
also independent of Ang II. This direct prorenin-induced
effect involved activation of three members of the
MAP kinase family, that is p38, ERK1/2, and Jnk. A similar
renin/(pro)renin-induced activation of p38 and ERK1/2
MAP kinases has been proposed in mesangial cells and
cardiomyocytes.8,24 We therefore hypothesize that part of the
renal injury in the clipped kidney after antihypertensive
therapy may be caused by profibrotic signaling of the
(pro)renin receptor after binding of its ligands prorenin or
renin.
The ultimate proof that the (pro)renin receptor has
profibrotic effects in the clipped kidney should be derived
from the effects of blood pressure lowering in Goldblatt
hypertensive (pro)renin receptor knockout mice. However,
the ablation of the (pro)renin receptor in embryonic stem
cells is not compatible with their participation in embryonic
development after injection into blastocysts.25 Unfortunately,
the renin inhibitor aliskiren is also not a promising option as
this drug is unlikely to interfere with renin binding to the
(pro)renin receptor.9,24
In summary, our data provide the first observation of an
upregulation of the (pro)renin receptor in the clipped kidney
of Goldblatt hypertensive rats. Blood pressure reduction
induces a several 1000-fold induction of renin and no
downregulation of its receptor. The dose-dependent increase
in renin expression and the dose-dependent increases of
vascular and tubulointerstitial injury strongly suggest a
profibrotic role for the (pro)renin receptor in the clipped
kidney. This clearly suggests that interventions targeting
renin or the (pro)renin receptor merit further evaluation for
the prevention or attenuation of renal failure in renovascular
hypertension.
MATERIALS AND METHODS
Goldblatt hypertension
Studies were performed in male Sprague-Dawley rats (Charles River,
Kisslegg, Germany). In rats weighing 120–140 g, two kidney, one clip
hypertension was induced as described previously.5–7 Only those rats
with systolic blood pressure 4160 mm Hg 6 weeks after surgery
were included in the protocol. Five groups of animals were studied:
normotensive control animals (n¼ 12), hypertensive rats (n¼ 16),
and hypertensive rats treated for 6 weeks with threefold increasing
doses of the vasopeptidase inhibitor AVE 7688 (kindly provided by
Sanofi-Aventis, Frankfurt, Germany) (50 mg/kg (n¼ 10), 150 mg/kg
(n¼ 11), 450 mg/kg food, (n¼ 10)). The drug was provided with
chow. Analyses were performed in three independent experiments
with 3-5 animals per group. In addition, four normotensive rats
were treated with AVE 450 mg/kg for 6 weeks and compared to four
nontreated controls. The data on tubulointerstitial damage in this
experiment have been published recently.7 Systolic blood pressure
was measured by tail cuff plethysmography (TSE-systems, Bad
Homburg, Germany) in awake rats.6 At the end of the experimental
protocol blood was drawn from the aorta into ice-cold syringes
containing heparin and the stenosed kidney was perfused with ice-
cold phosphate-buffered saline until the kidney blanched. The
kidneys were removed and slices were fixed in 4% buffered formalin.
RNA, reverse transcription-PCR, in situ hybridization,
histology, and biochemical measurements
Total RNA from the cortex of the clipped kidney was prepared
and real-time reverse transcription-PCR performed as described
(Pro)renin receptor Renin
(Pro)renin receptor Renin
Figure 4 | Immunohistochemical localization of renin and
(pro)renin receptor protein. Immunohistochemistry on consecutive
sections for (a and c) renal (pro)renin receptor and (b and d) renin in
antihypertensively treated Goldblatt rats. The (pro)renin receptor is
not expressed in the (a) preglomerular vessel (arrow), which is
(b) renin-positive (arrow). (c and d) In contrast, in tubuli (pro)renin
receptor expression and renin expression can be found in
consecutive sections (arrows).
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previously.7 The following rat specific PCR primers were used in this
study:
The presented results are the means of four independent PCRs
performed in duplicate with different RNAs pooled from two to
four rats. In situ hybridization procedures were performed as
described previously.7 Sections were stained with periodic acid-
Schiff to evaluate renal morphology. Renin and (pro)renin receptor
immunohistochemistry were performed as described previously
using polyclonal antibodies kindly provided by Dr. T Inagami
(Vanderbilt University School of Medicine, Nashville, USA)15 and
Dr G Ngyuen (INSERM, Paris, France).8 a-Smooth muscle cell actin
staining was performed as described.7 Planimetric examination of
the renin-positive preglomerular area was performed by means of a
Zeiss drawing tube in combination with a semiautomatic interactive
image analysis system (Morphomat 30, Zeiss, Go¨ttingen, Germany).
The outlines of the of the renin-positive preglomerular vessels were
traced manually and the mean area was determined as described.6
The number of renin-positive tubular profiles divided by all tubular
profiles was counted in five cortical high power fields in each kidney.
The plasma levels of renin and prorenin were measured as described
before. Prorenin was converted before measurement into renin by
trypsin.26
Statistical analysis
Results are expressed as means7s.e.m. For multiple comparisons,
we used the Kruskal–Wallis test with post hoc analysis according to
Mann–Whitney-U. P-values were adjusted for multiple testing to
Bonferroni (statistical significance was defined as Po0.05/k in case
of k comparisons).
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